Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016

Abstract Major advances have been made in the treatment of cancer with targeted therapy and immunotherapy; several FDA-approved agents with associated improvement of 1-year survival rates became available for stage IV melanoma patients. Before 2010, the 1-year survival were quite low, at 30%; in 201...

Full description

Bibliographic Details
Main Authors: Paolo A. Ascierto, Sanjiv S. Agarwala, Gennaro Ciliberto, Sandra Demaria, Reinhard Dummer, Connie P. M. Duong, Soldano Ferrone, Silvia C. Formenti, Claus Garbe, Ruth Halaban, Samir Khleif, Jason J. Luke, Lluis M. Mir, Willem W. Overwijk, Michael Postow, Igor Puzanov, Paul Sondel, Janis M. Taube, Per Thor Straten, David F. Stroncek, Jennifer A. Wargo, Hassane Zarour, Magdalena Thurin
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Journal of Translational Medicine
Subjects:
Melanoma
Immunotherapy
Cancer
Checkpoint blockade updates
Combination therapies
Biomarkers
Online Access:http://link.springer.com/article/10.1186/s12967-017-1341-2

Internet

http://link.springer.com/article/10.1186/s12967-017-1341-2

Similar Items